Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 5,000 Shares of Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction on Friday, April 6th. The shares were sold at an average price of $17.41, for a total transaction of $87,050.00. The sale was disclosed in a document filed with the SEC, which is available through this link.

Edward R. Conner also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Tuesday, March 6th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $24.78, for a total transaction of $123,900.00.
  • On Tuesday, February 6th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $18.49, for a total transaction of $92,450.00.

Shares of Sangamo Therapeutics stock traded up $0.85 during midday trading on Monday, reaching $17.80. 3,665,365 shares of the company’s stock traded hands, compared to its average volume of 2,179,161. The company has a market capitalization of $1,463.45, a P/E ratio of -25.43 and a beta of 2.80. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 0.13. Sangamo Therapeutics Inc has a 52 week low of $4.05 and a 52 week high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. The business had revenue of $13.08 million for the quarter, compared to the consensus estimate of $11.10 million. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. Sangamo Therapeutics’s revenue for the quarter was up 46.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.14) EPS. equities research analysts predict that Sangamo Therapeutics Inc will post -0.15 earnings per share for the current year.

A number of equities research analysts have issued reports on SGMO shares. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Barclays reissued a “buy” rating and set a $30.00 target price on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Piper Jaffray set a $25.00 target price on shares of Sangamo Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Jefferies Group restated a “buy” rating on shares of Sangamo Therapeutics in a report on Friday, February 23rd. Finally, Wedbush restated a “hold” rating and set a $8.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 13th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Sangamo Therapeutics has an average rating of “Buy” and an average target price of $20.83.

Several institutional investors have recently added to or reduced their stakes in SGMO. Alexandria Capital LLC bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $15,179,000. Tocqueville Asset Management L.P. raised its holdings in Sangamo Therapeutics by 105.0% in the 4th quarter. Tocqueville Asset Management L.P. now owns 665,890 shares of the biopharmaceutical company’s stock worth $10,921,000 after acquiring an additional 341,075 shares during the period. Goldman Sachs Group Inc. raised its holdings in Sangamo Therapeutics by 58.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 911,512 shares of the biopharmaceutical company’s stock worth $14,948,000 after acquiring an additional 336,107 shares during the period. Point72 Asset Management L.P. raised its holdings in Sangamo Therapeutics by 93.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 693,300 shares of the biopharmaceutical company’s stock worth $10,400,000 after acquiring an additional 335,595 shares during the period. Finally, Two Sigma Advisers LP raised its holdings in Sangamo Therapeutics by 908.6% in the 4th quarter. Two Sigma Advisers LP now owns 290,479 shares of the biopharmaceutical company’s stock worth $4,764,000 after acquiring an additional 261,679 shares during the period. Institutional investors and hedge funds own 64.68% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/09/insider-selling-sangamo-therapeutics-inc-sgmo-vp-sells-5000-shares-of-stock.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply